A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)
- Determine temporal changes in leukemic cell NF-kB activity when choline magnesium
trisalicylate is administered during induction chemotherapy in patients with newly
diagnosed acute myeloid leukemia.
- Determine toxicities of this regimen in these patients.
- Determine patterns of leukemic cell gene expression in patients treated with this
- Determine if NF-kB modulation results in enhanced apoptosis in patients treated with
OUTLINE: This is an open-label, pilot, parallel-group study.
Patients receive oral choline magnesium trisalicylate every 8 hours for 48 hours during
induction chemotherapy as determined by the primary physician.
Blood is collected at baseline, 24 hours, and 48 hours to assess for changes in NF-kB
expression, apoptosis, and gene expression in leukemic cells.
PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Temporal changes in leukemic cell NF-kB activity
Roger Strair, MD, PhD
Cancer Institute of New Jersey
United States: Federal Government
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|